Greater transparency needed in publishing information from clinical trials

An initiative from the drugs regulator, the European Medicines Agency, to commit to releasing all of the information from clinical trials once the marketing authorization process has ended, which has been greeted with cautious optimism by proponents of access to data but with much less enthusiasm by the pharmaceutical industry, sparks an interesting debate on the role of medical journals in publishing drug data, according to the Editors of PLOS Medicine.

Writing in an Editorial, the Editors state: "As 2013 begins, it is clear that critical times lie ahead for the publishing of , which may define the relationship between and the public for many years to come."

The Editors argue: "It is no longer going to be the case, if it ever was, that a trial report published in a journal will be sufficient as the record of a trial—and if journals are not careful, such reports will become unnecessary as well."

The Editors continue: "So in addition to this being a critical time in the relationship of pharmaceutical companies to society in general, it seems that this is a good time to renegotiate the relationship between pharmaceutical companies and ."

As data become more available for reanalysis, the Editors explain that report of a trial sanctioned by the pharmaceutical company and published in a journal will no longer be considered the definitive report of the trial. Instead, this report will become just one part of the large volume of information available around a trial, to be considered in conjunction with all analyses and data.

Over the course of 2013 as EMA defines the terms of reference for the release of data the importance of journal articles' reports of a trial will change. According to the Editors, "Some journals will find this harder to adjust to than others, especially those whose business model is heavily dependent on reprints of pharmaceutical companies' versions of trial reports."

More information: The PLOS Medicine Editors (2013) Getting More Generous with the Truth: Clinical Trial Reporting in 2013 and Beyond. PLoS Med 10(1): e1001379. doi:10.1371/journal.pmed.1001379

Funding: The authors are each paid a salary by the Public Library of Science, and they wrote this editorial during their salaried time.

add to favorites email to friend print save as pdf

Related Stories

Half of trials supporting FDA applications go unpublished

Sep 23, 2008

Over half of all supporting trials for FDA-approved drugs remained unpublished 5 years after approval, says new research published in this week's PLoS Medicine. The most important trials determining efficacy, and those with s ...

Recommended for you

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

Safety problems at US germ labs acknowledged

Jul 16, 2014

(AP)—The director of the U.S. Centers for Disease Control and Prevention acknowledged Wednesday that systemic safety problems have for years plagued federal public health laboratories that handle dangerous ...

User comments